California Affordable Drug Manufacturing Act of 2020: opioid antagonists.
Vote required
Majority
Fiscal committee
No
Appropriation
No
Current location
Health
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed Assembly
- Passed Senate
- To Governor
- Became Law
Overview
This bill modifies the California Affordable Drug Manufacturing Act of 2020 to prevent state agencies from awarding non-competitive contracts for opioid antagonists. Specifically, it prohibits contracts with companies that have participated in multistate settlements related to the opioid crisis. Any existing contracts violating this provision are void and unenforceable, retroactively applying to contracts signed before January 1, 2026.
Key provisions
- Prohibits non-competitive contracts for opioid antagonists.
- Applies to state agencies purchasing opioid antagonists.
- Specifically targets companies involved in opioid settlement agreements.
- Existing contracts violating the provision are void.
- Retroactive application to contracts before January 1, 2026.
- Defines ‘opioid antagonist’ as naloxone hydrochloride or FDA-approved opioid reversal drugs.
Who is affected
- State Agencies
- Pharmaceutical Companies
- Healthcare Providers
- Taxpayers
- Consumers
Notable changes
- Adds a restriction to the California Affordable Drug Manufacturing Act of 2020.
- Creates a specific prohibition on contracts with opioid settlement participants.
- Imposes a retroactive effect on existing contracts.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
1 on record
Primary sponsor
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours